Home Science White Blood Cells As Double Agents in Breast Cancer

White Blood Cells As Double Agents in Breast Cancer

0
White Blood Cells As Double Agents in Breast Cancer

White Blood Cells Cancer Spread Art

A new study reveals that VEGF-C-producing tumor-associated macrophages in breast cancer paradoxically reduce lung metastasis and increase lymph node metastasis, offering new insights for breast cancer treatment strategies. Credit: SciTechDaily.com

Recent research highlights the dual role of VEGF-C-producing macrophages in breast tumors, potentially guiding metastasis to less harmful areas, opening new avenues for targeted cancer therapies.

A new study from Karolinska Institutet published in Cell reports shows that tumor-associated macrophages, which are white blood cells that are found in breast tumors, can both help and hinder the spread of cancer cells to other organs. The researchers found that macrophages that produce a substance called VEGF-C reduce the spread of breast cancer to the lungs but increase the spread to the lymph nodes. This may have implications for the prognosis and treatment of breast cancer.

Understanding Breast Cancer and the Role of TAMs

Breast cancer is one of the most common cancers in the world, and most cases are hormone-dependent and can be treated with hormone therapy. But even several years after diagnosis, breast cancer can spread to other parts of the body, such as lungs, brain, and bone marrow. It is not entirely clear what causes this long-term risk, but a possible factor is the white blood cells called tumor-associated macrophages (TAMs). TAMs are abundant in breast tumors, playing a dual role in facilitating and impeding the spread of cancer cells. Specifically, perivascular TAMs, a subset wrapped around vessels, regulate blood vessel function and guide or block cancer cell entry into the vasculature, impacting their potential spreading to other organs.

Dual Effects of VEGF-C Producing TAMs

Associate Professor Charlotte Rolny at the Department of Oncology-Pathology and colleagues have studied a special type of TAMs that produces a substance called VEGF-C. This substance is known to affect the formation of new lymphatic vessels in tumors, which can facilitate the transport of cancer cells to other organs. However, the researchers discovered that TAMs that express VEGF-C have a dual effect: they reduce the spread of breast cancer to the lungs but increase the spread to the lymph nodes at the same time.

Clinical Implications and Mechanisms

The researchers also examined this relationship in clinical data from patients with breast cancer. They found that the presence of VEGF-C-positive TAMs was linked to a lower severity of the disease. It seems, therefore, that these TAMs are not only helpers of metastasis, but also strategic directors, who steer the cancer cells to less harmful routes.

How do these TAMs do this? The researchers suggest two possible mechanisms. First, VEGF-C-expressing TAMs normalize the tumor’s blood vessels, so that they become more organized and less leaky. Second, these macrophages stimulate lymphangiogenesis, that is, the formation of new lymphatic vessels, which facilitate the spread of cancer cells to the lymph nodes.

Conclusion and Therapeutic Potential

In summary, the paradoxical role of VEGF-C-expressing TAMs shows a fine-tuned orchestration within the tumor environment. Rather than merely facilitating metastasis, these macrophages emerge as strategic directors, who influence the destination of cancer cells. Understanding this process offers potential insights for therapeutic interventions, possibly by exploiting the paradox to prevent metastasis or redirect it to less harmful routes.

Reference: “VEGF-C-expressing TAMs rewire the metastatic fate of breast cancer cells” by Kaveri Banerjee, Thomas Kerzel, Tove Bekkhus, Sabrina de Souza Ferreira, Tatjana Wallmann, Majken Wallerius, Laura-Sophie Landwehr, Dennis Alexander Agardy, Nele Schauer, Anna Malmerfeldt, Jonas Bergh, Margarita Bartish, Johan Hartman, Arne Östman, Mario Leonardo Squadrito and Charlotte Rolny, 1 December 2023, Cell Reports.
DOI: 10.1016/j.celrep.2023.113507

The research was mainly funded by the Swedish Research Council, the Swedish Cancer Society, and Radiumhemmet’s research funds.

LEAVE A REPLY

Please enter your comment!
Please enter your name here